Coagulation Factor Deficiency Market to Witness Significant Innovation and Growth by 2034
The Coagulation Factor Deficiency market is evolving rapidly, fueled by advances in gene therapy, long-acting clotting factors, and better prophylaxis. DelveInsight's report covers epidemiology and treatments for Hemophilia A, B, and rare factor deficiencies (FVII, FXI, FXIII). AAV-based gene therapies are driving new treatment goals and improving outcomes, especially for underserved patients.
DelveInsight's ' Coagulation Factor Deficiency Market Report ' delivers detailed analysis of market dynamics, historical and forecasted epidemiology, and emerging therapies across the 7MM (US, EU5, and Japan), highlighting key players and trends driving this rare disease segment.
Some of the Key Facts of the Coagulation Factor Deficiency Market Report:
• In 2023, the coagulation factor deficiency market in the 7MM was valued at approximately USD 13.5 billion.
• The US led the market, contributing around USD 7.2 billion.
• There were about 105K prevalent cases across the 7MM, with the US accounting for nearly 34K.
• Hemophilia A was the most common subtype among all coagulation factor deficiencies.
• Marketed drugs for coagulation factor deficiency include ESPEROCT (Novo Nordisk), JIVI (Bayer), and WILATE (Octapharma).
• In March 2025, the FDA approved QFITLIA (fitusiran) for routine prophylaxis to reduce bleeding episodes in patients (12+) with hemophilia A or B, with or without factor VIII or IX inhibitors.
• In December 2024, Novo announced that the FDA approved concizumab, its tissue factor pathway inhibitor (TFPI) antagonist, as a once-daily treatment to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A or B with inhibitors.
• In October 2024, Novo Nordisk received support from European regulators for the approval of its anti-TFPI antibody, Alhemo (concizumab), as a preventive treatment for hemophilia. The company stated that, if approved, this therapy would provide the first subcutaneous prophylactic treatment to be administered once daily for individuals with hemophilia A or B who have inhibitors.
• In March 2024, ReciBioPharm signed a collaboration agreement with GeneVentiv Therapeutics, a preclinical gene therapy company, to advance the development of an adeno-associated virus (AAV)-based universal gene therapy for hemophilia, and reportedly the first to treat hemophilia patients with inhibitors.
• Emerging coagulation factor deficiency drugs include Concizumab, Fidanacogene Elaparvovec, RG6357 (SPK-8011), Fitusiran, Marstacimab, Giroctocogene Fitelparvovec, NNC0365-3769 A (MIM8), BT524, SerpinPC, STSP-0601, Marzeptacog Alfa, AB023, BAY2599023, OPK88005, and others.
• Leading companies in the coagulation factor deficiency market include Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (ApcinteX), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, OPKO Health, Inc., and others.
• The rising incidence of coagulation factor deficiencies, along with ongoing advancements in treatment options, is driving the demand for more effective therapies for these conditions.
To know in detail about the coagulation factor deficiency market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Coagulation Factor Deficiency Market Forecast
Coagulation Factor Deficiency Overview
Coagulation factor deficiencies, also referred to as bleeding or clotting disorders, are a group of inherited or acquired conditions caused by the absence or dysfunction of specific proteins that are essential for blood clotting. These proteins, known as coagulation factors, are vital for halting bleeding by forming clots to close off damaged blood vessels.
There are 13 coagulation factors, each numbered from I to XIII, that work together in a complex process to maintain hemostasis. Deficiencies in any of these factors can lead to abnormal bleeding, with severity varying based on the specific factor affected and the extent of the deficiency.
Get a free sample of the coagulation factor deficiency market report with key insights and emerging therapies here:
Coagulation Factor Deficiency Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Coagulation Factor Deficiency Epidemiology Segmentation:
The coagulation factor deficiency epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Total diagnosed prevalent cases
• Factor-specific prevalent cases
Download the report to understand which factors are driving coagulation factor deficiency epidemiology trends @ Coagulation Factor Deficiency Epidemiology Forecast
Coagulation Factor Deficiency Drugs Uptake, and Pipeline Development Activities
The coagulation factor deficiency drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the coagulation factor deficiency market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.
Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.
The report further delves into the coagulation factor deficiency pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.
Coagulation Factor Deficiency Market Strengths
• New gene therapies for coagulation factor deficiencies, like Hemophilia A and B, offer potential long-term or curative solutions.
• Better awareness and diagnostic tools are enabling earlier detection and more effective management.
Coagulation Factor Deficiency Market Weaknesses
•Many therapies, particularly gene therapies, remain expensive, limiting accessibility.
• Advanced therapies are not widely accessible in lower-income regions due to cost and healthcare limitations.
Scope of the Coagulation Factor Deficiency Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Coagulation Factor Deficiency Therapies: Concizumab, Fidanacogene Elaparvovec, RG6357 (SPK-8011), Fitusiran, Marstacimab, Giroctocogene Fitelparvovec, NNC0365-3769 A (MIM8), BT524, SerpinPC, STSP-0601, Marzeptacog Alfa, AB023, BAY2599023, OPK88005, and others.
• Key Coagulation Factor Deficiency Companies: Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (ApcinteX), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, OPKO Health, Inc., and others.
• Coagulation Factor Deficiency Therapeutic Assessment: Coagulation factor deficiency, currently marketed, and coagulation factor deficiency emerging therapies
• Coagulation Factor Deficiency Market Dynamics: Coagulation factor deficiency market drivers and Coagulation Factor Deficiency market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Coagulation Factor Deficiency Unmet Needs, KOL's views, Analyst's views, Coagulation Factor Deficiency Market Access and Reimbursement
To learn more about the key players and advancements in the coagulation factor deficiency treatment landscape, visit the Coagulation Factor Deficiency Market Analysis Report
Table of Contents
1. Coagulation Factor Deficiency Market Report Introduction
2. Executive Summary for Coagulation Factor Deficiency
3. SWOT analysis of Coagulation Factor Deficiency
4. Coagulation Factor Deficiency Patient Share (%) Overview at a Glance
5. Coagulation Factor Deficiency Market Overview at a Glance
6. Coagulation Factor Deficiency Disease Background and Overview
7. Coagulation Factor Deficiency Epidemiology and Patient Population
8. Country-Specific Patient Population of Coagulation Factor Deficiency
9. Coagulation Factor Deficiency Current Treatment and Medical Practices
10. Coagulation Factor Deficiency Unmet Needs
11. Coagulation Factor Deficiency Emerging Therapies
12. Coagulation Factor Deficiency Market Outlook
13. Country-Wise Coagulation Factor Deficiency Market Analysis (2020–2034)
14. Coagulation Factor Deficiency Market Access and Reimbursement of Therapies
15. Coagulation Factor Deficiency Market Drivers
16. Coagulation Factor Deficiency Market Barriers
17. Coagulation Factor Deficiency Appendix
18. Coagulation Factor Deficiency Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Older adults dying from unintentional falls
Older adults dying from unintentional falls A new report shows older adults are dying more from unintentional falls leads MedicalWatch for June 19, 2025.
Globe and Mail
3 hours ago
- Globe and Mail
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology or cancer is one of the most sought-after areas in the pharma/biotech space. As the world at large continues to grapple with a significant increase in the number of cancer patients, the market for cancer medicines is expected to grow. Pfizer is one of the largest and most successful drugmakers in the field of oncology. Oncology sales comprise around 25% of its total revenues. Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. Both drugmakers have strong footholds in their respective target markets, delivering consistent returns to shareholders. In such a scenario, choosing one stock over another can be challenging. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice. The Case for Pfizer Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Approved drugs in the portfolio include Ibrance, Xtandi, Inlyta, Lorbrena, Bosulif, Braftovi, Mektovi, Orgovyx, Elrexfio and Talzenna. Among these, the breast cancer drug Ibrance is one of the top revenue generators. The acquisition of Seagen in December 2023 strengthened PFE's oncology portfolio by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. This initiative boosted oncology sales in 2024 and the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline and their successful development should further strengthen its portfolio. PFE is working on the label expansion of many of its cancer drugs that should boost sales. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym. Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. Apart from oncology, Pfizer's portfolio has a variety of drugs and vaccines for diseases like COVID-19, inflammation & immunology diseases, rare diseases and migraine, among others. The Case for Bristol Myers BMY is focused on extending and strengthening its leadership in immuno-oncology (IO), as well as diversifying beyond IO. Leading IO drug Opdivo, approved for several cancer indications, drives its oncology franchise along with Yervoy and Opdualag. The FDA recently granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. Per BMY, this new subcutaneous formulation of Opdivo should help extend the reach and impact of its immuno-oncology franchise to patients into the next decade. Reblozyl, approved for first-line MDS-associated anemia, continues to drive market share within the larger first-line ring sideroblasts negative population. The CAR-T cell therapy Breyanzi is approved to treat the broadest array of B-cell malignancies. BMY has also been active on the acquisition front to expand its oncology portfolio/pipeline. In 2024, BMY acquired Mirati, a commercial-stage targeted oncology company, obtaining the rights to commercialize lung cancer medicine Krazati and to further develop several clinical assets, including PRMT5 Inhibitor. Krazati, a KRAS inhibitor, is approved for second-line non-small cell lung cancer (NSCLC) and is in clinical development with a PD-1 inhibitor for first-line NSCLC. It is also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab. In addition, PRMT5 Inhibitor is a potential first-in-class MTA-cooperative PRMT5 inhibitor, which is advancing to the next stage of development. The acquisition of RayzeBio, a leader in the field of radiopharmaceuticals for solid tumor oncology, provided BMY with RYZ101, a late-stage asset, an investigational new drug engine and in-house manufacturing capabilities. In 2022, BMY acquired Turning Point and added lead asset, repotrectinib, and other clinical and pre-clinical stage assets to its pipeline. Repotrectinib was approved by the FDA in November 2023 and is marketed under the brand name Augtyro. Augtyro, a kinase inhibitor, is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. It is also intended for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. Bristol Myers is also focused on developing drugs with presence in hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. A Look at Estimates: PFE vs BMY The Zacks Consensus Estimate for PFE's 2025 sales implies a year-over-year decrease of 0.6%, and that for earnings per share (EPS) suggests a year-over-year decline of 1.61%. EPS estimates for 2025 and 2026 have moved north in the past 60 days. PFE's Estimate Movement The Zacks Consensus Estimate for BMY's 2025 sales implies a year-over-year decrease of 4.13% while that for EPS suggests an increase of 487.83%. The extraordinary EPS growth rate is attributed to an extremely low EPS figure in 2024 due to acquisition expenses. EPS estimates for both 2025 and 2026 have moved south in the past 60 days. BMY's Estimate Movement Price Performance and Valuation of PFE and BMY From a price-performance perspective, PFE has performed better than BMY so far this year. Shares of PFE have declined 6.8%, while those of BMY have lost 15.4%. The large-cap pharma industry has declined 0.3% in the said period. From a valuation standpoint, we use the P/E ratio of the large-cap pharma industry to compare these companies. Going by the same, PFE is slightly more expensive than BMY. PFE's shares currently trade at 7.77X forward earnings, higher than 7.22 for BMY. PFE and BMY's attractive dividend yield is a strong positive for investors. However, PFE's dividend yield of 7.2% is higher than BMY's 5.29%. Which Stock Is a Better Pick for Now? Large pharma/biotech companies are generally considered safe havens for investors interested in this sector. However, with both PFE and BMY stocks currently carrying a Zacks Rank #3 (Hold), choosing one over the other is a complex task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. PFE has a strong and diverse portfolio but faces challenges like declining sales of its COVID-19 products and U.S. Medicare Part D headwinds in 2025. Several of its key products face patent expirations. Nonetheless, drugs like Vyndaqel, Padcev and Eliquis, and newly acquired products should continue to drive top-line growth. BMY's efforts to revive the top line in the face of generic challenges for key drugs are commendable. However, we believe there is still time before the efforts reap harvest for the company. The outlook for 2025 indicates challenges as of now. Hence, PFE is a better pick at present (despite its slightly pricey valuation), primarily due to the diversity of its portfolio and higher dividend yield compared to BMY. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report
Globe and Mail
3 hours ago
- Globe and Mail
Ibogaine by David Dardashti to Illuminate the Transformative Ibogaine Experience at Psychedelic Conference 2025
DENVER, CO - June 20, 2024 - Ibogaine by David Dardashti, a pioneer in holistic Ibogaine therapy, is proud to announce its prominent participation on Day 2 of the highly anticipated Psychedelic Conference 2025. David Dardashti and his team will offer individual descriptions of the unique Ibogaine experience, providing invaluable insights for each and every person at the conference seeking information regarding profound and lasting healing from addiction, trauma, and other mental health challenges. The core of the discussion will center on the therapeutic journey of Ibogaine. Patients describe the experience as a profound, introspective voyage through the past, present, and even potential future aspects of their lives. Unlike other therapies, Ibogaine often facilitates a unique perspective, allowing individuals to revisit significant life events and internalize them not from their own clouded emotional state, but from the detached, objective viewpoint of an outside observer. This remarkable shift in perspective enables deep understanding, reconciliation, and the ability to release long-held emotional burdens, fostering genuine personal growth and a renewed sense of purpose. Ibogaine by David Dardashti emphasizes highly individualized treatment protocols. The duration of an Ibogaine treatment varies, ranging from a focused 4-day experience to a comprehensive 21-day program, depending on the individual's specific needs, medical history, and the nature of their condition. Dosing is meticulously spread throughout the treatment period, starting with an initial transformative dose designed to interrupt cycles of dependence or deeply seated psychological patterns. This is often followed by carefully administered booster doses and, for longer programs, microdoses that support integration, neurogenesis, and sustained well-being in the weeks following the primary experience. This structured approach ensures both safety and maximal therapeutic benefit. "Ibogaine therapy, when administered with profound care and expertise, is not merely a detox; it is an awakening," says David Dardashti. "We guide individuals through a process that helps them confront their past, understand their present, and envision a healthier future. It's about empowering them to rewrite their narrative from a place of clarity and self-compassion, leading to truly sustainable transformation." Attendees of the Psychedelic Conference 2025 are invited to engage with Ibogaine by David Dardashti on Day 2 to gain a comprehensive understanding of this powerful plant medicine, its meticulous application, and the life-altering benefits it offers to those ready to embark on a journey of profound self-discovery and healing. About Ibogaine by David Dardashti: Ibogaine by David Dardashti is dedicated to providing safe, compassionate, and highly effective Ibogaine treatments. With a focus on individualized care, medical oversight, and comprehensive aftercare, the centers guide individuals towards sustainable recovery and improved mental well-being using the transformative properties of Ibogaine. About Psychedelic Conference 2025: The Psychedelic Conference 2025 is a leading international event bringing together researchers, practitioners, policymakers, and advocates to explore the latest advancements, therapeutic applications, and societal implications of psychedelic medicines.
